Preprint / Version 1

What Do We Know About and What Could Be the Strategy Adopted to Treat Mucormycosis on Post-COVID-19 Cases? Is It an Adjuvant Nanomaterial?


  • Gerson Nakazato Laboratory of Basic and Applied Bacteriology, Department of Microbiology, Biology Sciences Center, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazi
  • Wagner J Favaro Laboratory of Urogenital Carcinogenesis and Immunotherapy, Department of Structural and Functional Biology, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
  • Nelson Duran Institute of Biology, University of Campinas



Unfortunately, Coronavirus disease 2019 (COVID-19) remains a significant public health issue worldwide, mainly in the USA, India and Brazil. The 2nd wave of COVID-19 has reached India first. The country has been making great effort to stabilize its current condition but, unfortunately, mucormycosis infection (or black fungus) associated with COVID-19 has emerged as another threat to the country and, most likely, to Brazil. It may have happened due to excessive glucocorticoid using, since the widespread administration of this drug can lead to secondary fungal infections. Mucormycosis is generated by a group of molds called mucormycetes; it is a rare, although likely fatal, contamination when patients are not properly treated. The concerning factor lies on the fact that the high COVID-19 incidence recorded in the first wave of it has increased even faster in its second wave in India; there have been some concerning cases in Brazil, as well. The current overview addresses the current therapies used to treat mucormycosis worldwide, as well as potential and new drugs for such a specific treatment. Anti-mucormycosis adjuvants and nanomaterials are the most interesting alternatives to treat patients with post-COVID-19 mucormycosis.


Covid-19, mucormycosis, Nanomaterials


Download data is not yet available.


Andersen, P.M. 2021.

Attanasio, J., Wherry, E.J. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 2016; 44: 1052-1068.

Alonso, J.C.C., Reis, I.B., Gonçalves, J.M., et al. Oncotherad immunotherapy elicits promising responses in Bacillus Calmette-Guérin-unresponsive non–muscle invasive bladder cancer: Results from phase I/II study. J. Clin. Oncol. 2020; 38: e17048.

Barratt, D.M., Van Meter, K., Asmar, P., et al. Hyperbaric oxygen as an adjunct in zygomycosis: Randomized controlled trial in a murine model. Antimicrob. Agents Chemother. 2001; 45: 3601-3602.

Bellanger, A.P., Tatara, A.M., Shirazi, F., et al. Statin concentrations below the minimum inhibitory concentration attenuate the virulence of Rhizopus oryzae. J. Infect. Dis. 2016; 214: 114-121.

Brunet K, Rammaert B, Mucormycosis treatment: recommendations, latest advances, and perspectives. J. Mycol. Med. 2020; 30: 101007.

Caramalho, R., Maurer, E., Binder, U., et al. Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob. Agents Chemother. 2015; 59: 3663-3665.

CDC-2021. Mucormycosis Statistic ( June 5, 2020. Archived from the original on May 22, 2021.

Cornely, O.A., Arikan-Akdagli, S., Dannaoui, E., et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014; 20: 5-26.

Dannaoui E. Antifungal resistance in Mucorales. Int. J. Antimicrob. Agents. 2017; 50: 617-621.

Dannaoui, E., Lackner, M.. Special Issue: Mucorales and Mucormycosis. J. Fungi. 2020; 6: 6.

Durán, N., Fávaro, W.J. Immunomulators acting on Covid-19: Actual knowledge and perspectives. Preprints (MDPI) 2020a; 2020070090. doi: 10.20944/ preprints202007. 0090.v1.

Durán, N., Fávaro, W.J. Immunomodulators acting on Covid-19: Actual knowledge and perspectives. J. Appl. Microb. Res. 2020b; 3: 37-44.

Alonso, J.C.C., Delafiori, J., Mariano, V.M., dos Santos, L.A., Busanello, E.N.B., Rocha, A.R., Durán, N., Catharino, R.R., Fávaro, W.J. Nano-immunotherapy accelerates recovery of patient with Covid-19: Clinical analysis and metabolomics. J. Phys.: Conf. Ser. In press (2021).

Fávaro. W.J., Lantas, S.R., Gonçalves, J.M., et al. Single-arm phase I/II study of the safety and efficacy of OncoTherad immunomodulator in patients BCG-refractory or relapsed non-muscle invasive bladder cancer. J. Clin. Oncol. 2019; 37: e16000.

Fisher, E.W., Toma, A., Fisher, P.H., et al. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J. Laryngol. Otol. 1991; 105: 575-577.

Garcia A, Fan YY, Vellanki S, et al. Nanoemulsion as an effective treatment against human-pathogenic fungi. bioRxiv Preprint. 2019a; doi:

Garcia, A., Fan, Y.Y., Vellanki, S., et al. Nanoemulsion as an effective treatment against human-pathogenic fungi. MSphere 2019b; 4: e00729-19.

Garg, D., Muthu, V., Sehgal, I.S., et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia. 2021; 186:289-298.

Gamaletsou, M.N., Sipsas, N.V., Kontoyiannis, D.P., et al. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-. Diagn. Microbiol. Infect. Dis. 2012; 74: 409-411.

Gamaletsou, M.N., Sipsas, N.V., Roilides, E., et al. Rhino-orbital-cerebral mucormycosis. Curr. Infect. Dis. Rep. 2012; 14: 423-434.

Gebremariam, T., Lin, L., Liu, M., et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J. Clin. Investig. 2016; 126: 2280-2294.

Gil-Lamaignere, C., Simitsopoulou, M., Roilides, E.. et al. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J. Infect. Dis. 2005; 191: 1180-1187.

Grimaldi, D., Pradier, O., Hotchkiss, R.S., et al. Nivolumab plus interferon-? in the treatment of intractable mucormycosis. Lancet Infect. Dis. 2017; 17: 18.

Gunalan, S., Sivaraj, R., Rajendran, V. Green synthesized ZnO nanoparticles against bacterial and fungal pathogens. Prog. Nat. Sci. Mater. 2012; 22: 693-700.

Hubel, K., Dale, D.C., Engert, A., et al. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J. Infect. Dis. 2001; 183: 321-328.

Hunstad, D.A., Cohen, A.H., St Geme, J.W. Successful eradication of mucormycosis occurring in a pulmonary allograft. J. Heart Lung Transplant. 1999; 18: 801-804.

Herbrecht, R., Letscher-Bru, V., Bowden, R.A., et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 460-466.

Ibrahim, A.S., Gebremariam, T., Fu, Y., et al. The iron helator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Investig. 2007; 117: 2649-2657.

John, B.V., Chamilos, G., Kontoyiannis, D.P. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin. Microbiol. Infect. 2005; 11: 515-517.

Kathiravan, V., Ravi, S., Ashokkumar, S., et al. Green synthesis of silver nanoparticles using Croton sparsiflorus morong leaf extract and their antibacterial and antifungal activities. Spectrochim. Acta Part A: Mol. Biomol. Spectros. 2015; 139: 200-205.

Kontoyiannis, D.P. Mucormycosis. NORD (National Organization for Rare Disorders). Archived from the original on May 26, 2021.

Lim, K.K., Potts, M.J., Warnock, D.W. et al. Another case report of rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin. Infect. Dis. 1994; 18: 653-654.

Marty, F.M., Ostrosky-Zeichner, L., Cornely, O.A., et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016; 16: 828-837.

Medda, S., Hajra, SA., Dey, U., et al. Biosynthesis of silver nanoparticles from Aloe vera leaf extract and antifungal activity against Rhizopus sp. and Aspergillus sp. Appl. Nanosci. 2015; 5: 875-880.

Mekonnen, Z.K., Ashraf, D.C., Jankowski, T., et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast. Reconstr. Surg. 2021; 37: e40-e80.

Morales-Franco, B., Nava-Villalba, M., Medina-Guerrero, E.O., et al. Host-pathogen molecular factors contribute to the pathogenesis of Rhizopus spp. in diabetes mellitus. Curr. Trop. Med. Rep. 2021; 8: 6-17.

Moreira, J., Varon, A., Galhardo, M.C., et al. The burden of mucormycosis in HIV-infected patients: A systematic review. J. Infect. 2016; 73: 181-188.

Moses, A.E., Rahav, G., Barenholz, Y., et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin. Infect. Dis. 1998; 26: 1430-1433.

Munckhof, W., Jones, R., Tosolini, F.A., et al. Cure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B. Clin. Infect. Dis. 1993; 16: 183.

Nagappan, V., Deresinski, S. Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 2007; 45: 1610-1617.

Nucci, M., Engelhardt, M., Ha, K.. Mucormycosis in South America: A review of 143 reported cases. Mycoses. 2019; 62: 730-738.

Ogawa, T., Takezawa, K., Tojima, I., et al. Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin. Auris Nasus Larynx. 2012; 39: 224-228.

Pasero. D., Sanna, S., Liperi, C., et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020;

Rao, M.L., Savitramma, N. Biological synthesis of silver nanoparticles using Svensonia hyderabadensis leaf extract and evaluation of their antimicrobial efficacy. J. Pharm. Sci. Res. 2011; 3: 1117-1121.

Raut, A., Huy, N.T.. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir. Med. 2021;

Sahayaraj, K., Balasubramanyam, G., Chavali, M. Green synthesis of silver nanoparticles using dry leaf aqueous extract of Pongamia glabra Vent (Fab.), Characterization and phytofungicidal activity. Environ. Nanotechnol. Monitor. Manag. 2020; 14: 100349.

Shoham, S., Magill, S.S., Merz, W.G., et al. Primary treatment of mucormycosis with liposomal amphotericin B: Analysis of 28 cases. Med. Mycol. 2010; 48: 511-517.

Singh, A.K., Singh, R., Joshi, S.R., et al. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab, Syndr. 2021; doi: 10.1016/j.dsx.2021.05.019.

Sipsas, N.V., Gamaletsou, M.N., Anastasopoulou, A., et al. Therapy of Mucormycosis. J. Fungi. 2018; 4: 90.

Spellberg, B., Ibrahim, A.S., Chin-Hong, P.V., et al. The deferasirox-ambisome therapy for mucormycosis (DEFEAT Mucor) study: A randomized, double-blinded, placebo-controlled trial. J. Antimicrob. Chemother. 2012; 67: 715-722.

Tkatch, L.S., Kusne, S., Eibling, D. Successful treatment of zygomycosis of the paranasal sinuses with surgical debridement and amphotericin B colloidal dispersion. Am. J. Otolaryngol. 1993; 14: 249-253.

Tragiannidis, A., Groll, A.H. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin. Microbiol. Infect. 2009; 15 (Suppl. 5): 82-86.

Tissot, F., Agrawal, S., Pagano, L., et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopooietic stem cell transplant patients. Haematologica. 2017; 102: 433-444.

Vallabhaneni, S., Mody, R.K., Walker, T., et al. The global burden of fungal disease. In Fungal Infections.An Issue of Infectious Disease Clinics of North America (Sobel, Jack; Ostrosky-Zeichner, Luis. Eds.). Philadelphia: Elsevier. pp. 5–12. ISBN 978-0-323-41649-8.(2016).

Vidovic, A., Arsic-Arsenijevic, V., Tomin, D., et al. Proven invasive pulmonary mucormycosis successfully treated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report. J. Med. Case Rep. 2013; 7: 263.

Voltan, A.R., Quindós, G., Alarcón, K.P.M., et al. Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy? Inter. J. Nanomed. 2016; 11: 3715-3730.

Wani, A.H., Shah, M.A. A unique and profound effect of MgO and ZnO nanoparticles on some plant pathogenic fungi. J. Appl. Pharm. Sci. 2012; 2: 40-44.

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg. Med. 2020; 42: 264.e5-264.e8.